Edition cannis

Courtesy of FloraVega. Courtesy of Matrix. Courtesy of Medizin. Courtesy of Virtue. Courtesy of Fiore. Courtesy of Verano. Courtesy of Qualcan. Courtesy of Cannabiotix. In both Europe and the United States, the sales of unapproved cannabis products such as smokable flower and full spectrum oils dwarf those of approved pharmaceuticals. In Europe however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products.

In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals. However, no single cannabinoid drug has received widespread approval in the treatment of pain. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals - from - including Epidiolex, Sativex and Dronabinol.

The use of cannabinoids in the treatment of medical conditions offers major opportunities, but also challenges to anyone operating in the space. However, regulations are constantly shifting beneath the feet of operators and their ability to serve patients depends on their capacity to navigate a changing landscape of governance. The majority of medicinal cannabis is currently being prescribed in a medically non-traditional manner, with short patient-doctor interactions and approximate dosing of the active pharmaceutical ingredients e.

In both Europe and the United States US , the sales of unapproved cannabis products such as smoked flower and full- spectrum oils dwarf those of approved pharmaceuticals like Epidiolex, Marinol, Sativex and Cesamet which have been guided through the traditional approvals process. In Europe however, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as approved pharmaceutical products. In the US, sales of medical flower and vaporised products remain dominant amongst unapproved medicines, but there is also an increase in sales of pharmaceuticals, mainly Epidiolex.

The story of GW Pharmaceuticals, the producers of Epidiolex, is instructive regarding the challenges and opportunities of operating in the pharmaceutical cannabis space; taking over 20 years to generate considerable sales and facing several setbacks in clinical trials. The current medical cannabis market is bursting with innovation. The author has identified at least 30 late-stage clinical trials using cannabinoid therapeutics, any of which could have a large impact on the medicinal cannabis space.

Products with new routes of administration, such as metered inhalers and transdermal products, are currently making their way through the approvals process. Research and development on minor cannabinoids such as Cannabigerol CBG and Cannabichromene CBC is just beginning, with a lot of therapeutic promise but still with a lack of hard evidence. Many in the medical cannabis space are developing portfolios of patents to protect products and their methods of production.

The industry is yet to see a considerable amount of litigation, but this may soon change, as signalled by the case between GW Pharmaceuticals and Canopy Growth over proprietary methods of cannabinoid extraction. In the realm of patents, the looming expiration of market exclusivity on Epidiolex could soon offer opportunities to potential producers of generics to supply cheaper alternatives to patients suffering from rare forms of epilepsy.

Overall, the total potential for the use of medical cannabinoids in the pharmaceutical space has barely been scratched. To be approachable, to be elevated, for people who are less familiar or comfortable with cannabis. To work with Justin is really consistent with our mission. Bieber has used his celebrity status to be candid about his mental health journey.

The musician offered an intimate portrait of his struggles with mental health on his YouTube Original docuseries Seasons. The collaboration came together quickly, says Annes.

Peaches is a different product and strain for the Palms team. Typically, Palms is greenhouse-grown. Peaches is all indoor, full-flower, single strain prerolls. The Peaches is indoor-grown, and for that reason, it tests a little bit higher. All Peaches packs except Florida will come with a custom Peaches lighter. Once the survey closes, the results as a whole will be published on Canis Hoopus and in theory be sent to Gersson Rosas for review.

Cookie banner We use cookies and other tracking technologies to improve your browsing experience on our site, show personalized content and targeted ads, analyze site traffic, and understand where our audiences come from.

By choosing I Accept , you consent to our use of cookies and other tracking technologies. Filed under: Canis Pulsus. Canis Pulsus - Vol. XI: Ben Simmons Edition.